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The present studies assessed the level of tumor necrosis factor receptor (TNFR) expression in peripheral blood mononuclear
cells (PBMCs) subsets from patients with chronic HCV undergoing interferon α/ribavirin-based therapy (Ifn/R). Methods.T N F R
family member mRNA expression was determined using quantitative real-time PCR assays (RTPCRs) in PBMC from 39 HCV+
patientsand21controlHCV−patients.FurthersubsetanalysisofHCV+patients(untreated(U),sustainedvirologicalresponders
(SVR), and nonresponders (NR)/relapsers (Rel)) PBMC was performed via staining with anti-CD123, anti-CD33, anti-TNFR1 or
via RTPCR for TNFR1 mRNA. Results. A similar level of TNFR1 mRNA in PBMC from untreated HCV+ genotype 1 patients and
controls was noted. TNFR1 and TNFR2 mRNA levels in PBMC from HCV+ patients with SVR were statistically diﬀerent than
levels in HCV(−) patients. A signiﬁcant diﬀerence was noted between the peak values of TNFR1 of the CD123+ PBMC isolated
from SVR and the NR/Rel. Conclusion. Upregulation of TNFR1 expression, occurring in a speciﬁc subset of CD123+ dendritic
cells, appeared in HCV+ patients with SVR.
1.Introduction
Unlike infections by other human hepatitis viruses, hepatitis
C virus (HCV) infection of healthy immunocompetent
adults is persistent or prolonged in the majority of cases,
unlike hepatitis B, where it persist in the minority of
cases. HCV appears to have evolved strategies to evade
the human immune responses. Investigators have suggested
that viral interactions with tumor necrosis factor/tumor
necrosis factor receptor (TNF/TNFR) family members may
beimportantinimmuneevasion.Investigatorshavereported
that HCV core protein binds to the cytoplasmic domain
of TNFR1, speciﬁcally the “death domain,” which may
hinder or promote cell death during HCV infection [1]. In
addition, the HCV core protein binds to another TNFR fam-
ily member, lymphotoxin β receptor’s (LTβR) intracellular
domain, which is involved in signal transduction [2]. Inves-
tigators have also demonstrated that the HCV core protein
potentiates NF6B activation initiated by TNFα/TNFR and
LTα1β2/LTβR interactions, which, in turn may contribute to
the chronically activated, persistent state of HCV-infected
cells [3, 4]. Interference with signaling through members
of the TNF family of receptors may aﬀect the chronicity of
HCVviaaﬀectingeithercelldeathand/oractivationofNFκB
[1, 3, 4].
Of interest, other investigators have examined the rela-
tionship between HCV and the soluble TNF receptors
(sTNFR) in the blood. These sTNFR levels appear to peak
9 hours after the ﬁrst IFNα administration correlating with
IFNα serum levels [5]. Other investigators have noted higher
levels of TNF and sTNFRs in HCV+ patients than in HCV
(−) controls prior to treatment and postulated that high2 Hepatitis Research and Treatment
levels of sTNFR might modify host responses but found no
correlation between levels and response to therapy [6].
TNF receptors are present on the surface of a number
of cell subsets and play a role in a variety of functions.
For example, TNF/TNFR interactions are imperative for the
optimal proliferation and eﬀector functions of CD8+ T cells
[7, 8], whose antiviral eﬀects are essential for the clearance
of noncytopathic viruses, such as HCV. In addition, LTβR-
LIGHT/LTα1β2 i n t e r a c t i o n sh a v eb e e ni m p l i c a t e di nb o t h
optimal growth and eﬀector functions as well as costim-
ulation of CD8+T cells [9]. Similarly, TNFR is expressed
on macrophages, peripheral blood monocytes, and antigen
presenting cells (APCs), cells known to be important in viral
infections. Recently, HCV negative strand RNA has been
noted in the macrophages of 67% of sustained virological
responders to interferon-based therapies [10]. Others have
noted the importance of monocytes and dendritic cellsinthe
clearance of HCV [11–14] .T h er o l eo fT N F Ri nH C Vv i r a l
clearance may involve any of these cell subsets.
The largely chronic nature of HCV infection has been
attributed to an attenuated antiviral T-cell response. It
has been postulated that APC’s may become dysfunctional
in some way during HCV infection contributing to this
attenuation. Speciﬁcally, large deﬁcits in IFNα production
in plasmacytoid dendritic cells (PDCs) in HCV-infected
patients have been reported in [15]. In the same study
HCV-infected PDC displayed distinct immunophenotypic
features including an increased ability to stimulate a mixed
lymphocyte response (MLR) but lower HLA-DR and CD86
expression. This proﬁle suggested that HCV-infected PDC
were at an immature stage of diﬀerentiation [15].
The present studies were designed to quantify the mRNA
and protein levels of the TNF receptor family members,
includingTNFR1andTNFR2,inPBMCsduringIFNα-based
therapy of HCV+ patients. The results of these studies reveal
increased peak levels of TNFR1 mRNA levels in responders
to IFN-based therapies. Furthermore, by ﬂow cytometric
studies and western blot analysis, upregulation of TNFR1
protein expression was noted in speciﬁc PBMC subsets. The
increase in TNFR1 expression was speciﬁcally isolated in
PDC(CD11−and CD123high) ofHCV-infectedpatients who
responded to IFNα based therapies compared to control
patients and nonresponders.
2. Methods
2.1. Patients. Veteran patients >18 years of age with chronic
HCV were recruited to IFNα based treatment trials con-
ducted at the Dallas Veterans Aﬀairs Medical Center from
February 2002 through July 2005. Thirty-seven patients with
genotype 1 consented per institutional review board (IRB)
guidelines for blood draws at one or more time points,
including 0, 4, 8, 12, 24, and 48 weeks of therapy, where
the standard therapy (48 weeks of weight-based dosing of
1.5μg/kg of pegylated interferon α-2b and 13.5mg/kg of
(ribavirin) for genotype 1 patients was utilized. Thirteen
patients were sustained virological responders (SVR, HCV
RNA negative 24 weeks after end of therapy), 20 patients
were nonresponders (NR, persistently HCV RNA positive
during therapy), and 4 patients were relapsers (Rel, HCV
RNA negative during therapy but HCV RNA positive
after end of therapy). None of the patients analyzed had
received interferon prior to the initial blood draw. Similarly,
10HCV(−) patients and 11 patients with alcoholic liver
disease (ALD) or nonalcoholic fatty liver disease (NAFLD)
consented per IRB guidelines for a blood draw.
In a second set of patients, samples from 13 genotype
1HCV+ patients (5 SVR, 6 NR/Rel and 2HCV+ prior to
therapy) and 2HCV(−) control patients obtained during
therapy at <12, 16–24, or 25–44 weeks were collected for a
specialized cell subset analysis.
2.2. RNA Isolation and Real-Time PCR Primers. RNA was
isolated from PBMC’s at 0, 4, 8, 12, 24, and 48 weeks of
interferon/ribavirin (Ifn/R) treatment trials from 39HCV+
men, 10age- and sex- matched HCV(−) controls, and 11
age- and sex- matched controls with either alcoholic liver
disease (ALD) or nonalcoholic fatty liver disease (NAFLD).
Initially, 40–60cc of blood was obtained from HCV+
patientsandcontrols.PBMCswerethenseparatedbydensity
gradient centrifugation and then stored in TRIzol reagent
to stabilize the RNA. RNA was then extracted, precipitated,
and subjected to DNase treatment, and then the treated RNA
underwent reverse transcription.
In order to assess whether there were diﬀerences in
any speciﬁc cytokine receptors or TNF receptor family
members, 101 cDNA samples were utilized in a quantitative
real time PCR-based assay assessing the relative quantities
of cyclophilin, NGFR, CD30, TNFR1, TNFR2, LTβR, IL-
2Rα, CD27, FAS, and CD3. RNA from PDC (CD11− and
CD123high) and myeloid dendritic cells (MDC) (CD11+ and
CD123dim) from a control, SVR, and NR were isolated in an
identical fashion and utilized in a quantitative PCR assay for
TNFR1.
The primers utilized were obtained as follows. The NCBI
database was ﬁrst interrogated to ﬁnd the sequence of the
cytokine receptor or other receptors of interest and then
entered into the Primer Express software program in order
to generate a primer which was then optimized according to
the parameters of the real time PCR (Table 1). The threshold
cycle or Ct value, the lowest cycle in which ﬂuorescence was
detected during the exponential phase, was calculated where
the exponential phase of the reaction began.
2.3. Standardization and Comparison of Samples. The Ct
values were standardized using RNA isolated from cell lines
known to express high levels of the target genes. In order to
normalize across experiments, these values were compared
to the same standard for all experiments, that is RNA from
cell lines expressing high levels of TNFR or LTβR( P H A
activated lymphocytes and THP-1, resp.). The resulting cycle
thresholdvalueswerenormalizedtoendogenouscyclophillin
values and a calibrator value for each experiment. Raw cycle
threshold values for the no template control within each
experimentweresigniﬁcantlydiﬀerentthantheexperimental
valuesforcyclophillin,CD3ε,NGFR,CD30,TNFR1,TNFR2,Hepatitis Research and Treatment 3
Table 1: Real-Time PCR Primers.
Target Primer Sequence
Cyclophillin Fw 5 -TGCCATCGCCAAGGAGTAG-3 
Rv 5 -TGCACAGACGGTCACTCAAA- 3 
TNFR1 Fw 5 -CGCTACCAACGGTGGAAGTC- 3 
Rv 5  -CAAGCTCCCCCTCTTTTTCAG-3 
LTβRF w 5  -CGGGCCCCTCTAAAGGATT-3 
Rv 5 -GTGAAGTGTGGAACCCCAAAG-3 
TNFR2 Fw 5 -CAAGCCAGCTCCACAATGG-3 
Rv 5 -TGACCGAAAGGCACATTCCT-3 
NGFR Fw 5 -CCGTGGAGATGGGATGCTT-3 
Rv 5 -TTTCCACGAACCCCAAACC-3 
CD30R Fw 5 -GCTTTACTCTGGACCATAGGAAACA-3 
Rv 5 -CTCCTTAGCGTGAAATGTGAAAAA-3 
IL2Rα Fw 5 -CAGAAGTCATGAAGCCCAAGTG-3 
Rv 5 -GGCAAGCACAACGGATGTCT-3 
CD27 Fw 5 -TCGGCACTGTAACTCTGGTCTTC-3 
Rv 5 -CGACAGGCACACTCAGCATT-3 
FAS Fw 5 -CTTTTCGTGAGCTCGTCTCTGA-3 
Rv 5 -CTCCCCAGAAGCGTCTTTGA-3 
CD3 Fw 5 -CATCCCAAAGTATTCCATCTACTTTTC-3 
Rv 5 -CCCAGTCCATCCCCAGAGA-3 
LTβR, FAS, IL-2Rα, and CD27, verifying the presence of
cDNA for these receptors.
The comparison between control HCV(−) patients and
SVR, NR, and Rel were expressed as fold elevation above
control. The control population is deﬁned as both HCV(−)
patients with ALD or NAFLD (n = 9) and HCV(−)c o n t r o l
subjects (n = 10).
2.4. Western Blot Analysis. Whole PBMC’s from one SVR
with a high level of TNFR1 mRNA by real time PCR were
analyzed by Western blot in order to determine protein
levels of TNFR1. Whole PBMC’s were freeze-thawed twice,
suspended in PBS, and assayed for protein, and 20μgf r o m
one SVR and one control as well as 200ng of recombinant
human soluble TNF receptor 1 (R&D Systems, Minneapo-
lis/St. Paul, MN) were prepared for sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) in the pres-
ence of 2-mercaptoethanol, resolved on a 10% acrylamide
gel, and transferred to a nitrocellulose membrane. After
blocking in 5% milk in TBS (0.1mol/L NaCl and 0.4mmol/L
Tris, pH7.4), containing 0.05% sodium azide, the blot
was exposed to human soluble TNF receptor 1 polyclonal
detection antibody (R&D Systems). Bound antibody was
allowed to react with alkaline phosphatase-conjugated goat
antimouse IgG (Sigma Chemical Co., St. Louis, MO) [15].
2.5. Flow Cytometry. At 44 weeks of therapy, whole PBMCs
from a SVR and an NR were isolated from 40–60cc
whole blood by density gradient separation. In another
experiment, PBMCs from an SVR at 48weeks, NR at
24weeks, and control patient were isolated as previously
described for subset analysis. The PBMC’s from all patients
were suspended in staining buﬀer (0.5L HBSS, 0.5L PBS,
2% BSA, 0.02% sodium azide). Cells were labeled with
the FITC-labeled anti-TNFR1 Ab (FAB225F, R&D Systems)
or control FITC IgG16 (555748l, BD Pharmingen). The
samples designated for cell subset analysis were then stained
with CD33 (555748l, BD Pharmingen), CD14 (555748l,
BD Pharmingen), CD11 (555748l, BD Pharmingen), CD123
(555748l,BDPharmingen),orrelativeisotypecontrols.After
mAb staining and washing, all samples were ﬁxed in PBS
containing 1% paraformaldehyde at room temperature for
10minutes and stored at 4◦C until ﬂow cytometric analysis
as previously described in [16, 17]. Flow cytometric analysis
was performed on an FACscan (Becton Dickinson) and
used to determine the mean ﬂuorescence intensity (MFI)
of TNFR1 on all labeled cells. TNFR1 MFI ratios (TNFR1
MFI/isotype control MFI) were determined.
RNA from FAC sorted plamacytoid dendritic cells
(PDCs) (CD11− and CD123high) and myeloid dendritic cells
(MDCs) (CD11+ and CD123dim from a control, SVRs and
NR were utilized in a real time PCR assay for TNFR1.
2.6. Statistical Analysis. D e s c r i p t i v ed a t aw e r er e p o r t e da sa
mean for all standard deviation (SD) and median and range
inFigures1and2.Allresultswereanalyzedwithanintention
to treat analysis. Characteristics of treatment groups were
compared using student’s t-test. All results were analyzed
using an exact Fisher test. A “P” value of less than.05 was
considered to be signiﬁcant.
3. Results
3.1. PBMC Tumor Necrosis Factor Receptor (TNFR) mRNA
Levels from Responders to IFN Therapy Increased while Other
TNFR Family Members mRNA Levels Remained Stable. RNA
from PBMC of 23HCV+ patients was isolated prior to
the commencement of IFNα based therapy. Similarly, RNA
from PBMC’s of 10 HCV(−) controls and 11 patients with
ALD or NAFLD were also isolated. During the course of
48 weeks of IFNα based therapy, 80RNA samples were
isolated from PBMC’s from 13HCV+ responder [(SVR and
end of treatment responders (ETR)] patients and from
24NR patients. Quantitative real time PCR levels of TNFR1,
TNFR2,LTβR,FASR,CD30,CD27,andNGF,aswellasCD3ε
and IL-2Rα mRNA were assessed in available samples at 8,
12, 24, and/or 48 weeks of therapy (Table 2). In order to
normalize across experiments, these values were normalized
to the same standard for all experiments, that is, RNA from
cell lines expressing high levels of TNFR (PHA-activated
lymphocytes).
As noted, TNFR1 mRNA levels of PBMC from HCV+
responder patients were signiﬁcantly higher than levels from
control age- and sex- matched HCV(−)c o n t r o lp a t i e n t s
during the course of the IFNα based therapy (n = 26,
P = .033), while TNFR1 mRNA levels of PBMC’s from HCV
NR patients were not signiﬁcantly diﬀerent from controls
(n = 38, P = .20). Similarly, during the course of IFNα
based therapy, TNFR2 mRNA levels of PBMC from HCV+
responder patients were signiﬁcantly higher than levels in4 Hepatitis Research and Treatment
Table 2: TNFR1 Family Members’ mRNA Levels.
ControlHCV neg Responders∗ NR/Rel
Prior to Tx On Tx Prior to Tx On Tx
TNFR1
0.83 ±0.9
(n = 10)
1.2 ±1.53
(n = 11)∗∗
1.94 for all
2.43(n = 7)
7.09 for all
8.82(n = 26)(P = .033)∗∗
2.83 for all
2.87(n = 14)
2.31 for all
3.53(n = 38)(P = .20)∗∗∗
TNFR2
2.10 ±2.93
(n = 10)
2.03 ±1.34
(n = 5)∗∗
1.36 for all
1.22(n = 7) 5.93±7.61(n = 22)(P = .045)∗∗ 2.30 for all
2.67(n = 12)
2.57 for all
4.60(n = 33)(P = .41)∗∗
LTβR
1.67 ±1.01
(n = 10)
2.17 ±2.66
(n = 10)∗∗
1.21for all
1.24(n = 7) 1.49 ±1.64(n = 22)(P = .75)∗∗ 1.35 for all
1.35(n = 12)
2.47 for all
5.41(n = 34)(P = .66)∗∗
FASR 0.38 for all 0.54
(n = 3) 0.001(n = 1) 0.14 for all
0.40(n = 18)(P = .35)∗∗
0.01 for all
0.01(n = 6)
0.03 for all
0.07(n = 21)(P = .003)∗∗
CD30 0.37 for all
0.41(n = 6)
0.175 for all
0.06(n = 2)
0.61 for all
1.22(n = 21)(P = .65)∗∗
0.06 for all
0.07(n = 5)
0.61 for all
1.51(n = 20)(P = .71)∗∗
CD27 0.86 for all
0.49(n = 6)
0.77 for all
0.37(n = 2)
1.08 for all
0.65(n = 21)(P = .45)∗∗
1.10 for all
0.62(n = 5)
0.71 for all
0.62(n = 20)(P = .58)∗∗
NGF 0.75 for all
1.22(n = 6)
0.085 for all
0.007(n = 2)
1.85 for all
4.80(n = 22)(P = .59)∗∗
0.11 for all
0.19(n = 6)
1.37 for all
2.86(n = 18)(P = .62)∗∗
IL-2R for all 0.22 for all
0.39(n = 6)
0.175 for all
0.18(n = 2)
0.45 for all
0.63(n = 21)(P = .41)∗∗
0.10 for all
0.22(n = 6)
0.05 for all
0.10(n = 19)(P = .09)∗∗
CD3 1.43 for all
0.71(n = 3) 1.3(n = 1) 4.71 for all
12.62(n = 17)(P = .67)∗∗
1.67 for all
1.07(n = 5)
6.93 for all
21.06(n = 18)(P = .66)∗∗
∗Include End of treatment responders (ETR) and SVR.
∗∗Mean value for control liver disease patients, HCV negative.
∗∗∗P-value compared to control (HCV negative, age and sexed matched).
the control age- and sex- matched HCV(−) patients (n =
22, P = .045) while no diﬀerence was noted relative to
levels in HCV NR and controls (n = 33, P = .41).
No other signiﬁcant increases were observed in the other
TNFR family members or T-cell-associated mRNA (CD3ε
or IL-2Rα) levels of PBMC isolated from responders or NR
(Table 2). In summary, PBMC’s mRNA levels of TNFR1
and TNFR2 from responders to IFNα based therapy were
statistically diﬀerent than levels in control HCV(−)a g e -a n d
sex- matched patients.
3.2. TNFR1 and TNFR2 mRNA Levels from HCV+ Patients
Prior to Treatment and Control Patients Were Similar. In
light of diﬀerences between levels of TNFR1 and TNFR2
mRNA in PBMC of responders and nonresponders during
the therapy, further analysis of the TNFR1 and TNFR2 levels
was performed. RNA was isolated from PBMCs of 23HCV+
untreated patients, 10 control HCV(−) patients, and 11
patients with ALD or NAFLD. TNFR1 and TNFR2 mRNA
levels were similar in both HCV infected and control groups
[1.02 ± 1.25 (n = 21) versus 2.53 for all 2.71 (n = 23) and
1.95 for all 2.42 (n = 15) versus 2.07 for all2.45 (n = 18)]
(Figure 1, panels A and B). Quantitative real time PCR
revealednodiﬀerencebetweeninitiallevelsofTNFR1mRNA
in the HCV+ genotype 1 patients and control non-HCV+
patients (P = .08) nor between HCV+ genotype 1 patients
and patients with non-HCV liver disease (P = .17). Similar
results between initial TNFR1 RNA levels in control (HCV
negative and non-HCV liver disease) and initial levels in
HCV+patientswerenoted[median0.59(Range:0.02–5.42)]
versus [median 1.52 (Range: 0.06–11.65)] (Figure 1,p a n e l
A). TNFR2 mRNA levels were not signiﬁcantly diﬀerent
between HCV+ patients prior to therapy and either HCV(−)
control patients or HCV(−) patients with liver disease (P =
.88 and .95), (Figure 1, panel B).
3.3. Peak TNFR1 mRNA Levels Were Signiﬁcantly Diﬀerent
between SVR and Nonresponders. In order to determine
whether the elevation of TNFR1 or TNFR2 mRNA was
above control levels at any point during IFNα based therapy
(4, 8, 12, 24 and 48 weeks), 12 genotype 1HCV+ SVR
and 25 genotype 1HCV+ patients NR/Rel were evaluated.
TNFR1 and TNFR2 mRNA elevations were signiﬁcantly
more frequent in SVR versus NR/Rel.
The peak TNFR1 mRNA levels in PBMC of genotype
1HCV+patientsat4,8,12,24,or48weeksweregreaterthan
2 SD (2.63 fold elevation) above mean TNFR1 mRNA levels
from HCV(−) controls in 7/12 (58%) sustained virological
responders (SVR), but in only 5/21 (28%) genotype 1NR
and2/4(50%)genotype1Rel.Furthermore,thepeakTNFR1
mRNA levels from responders were signiﬁcantly higher than
t h ep e a kT N F R 1m R N Al e v e l si nN Ra n dR e l( P = .0023)Hepatitis Research and Treatment 5
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Figure 1: TNFR1 and TNFR2 mRNA levels were not diﬀerent between HCV(−)/ALD/NAFLD control patients and genotype 1HCV+
patients prior to treatment. TNFR1 mRNA levels of PBMC’s isolated from 10HCV(−) controls, 11 ALD/NAFLD controls, and 23HCV+
patients prior to therapy were ascertained by real time PCR (Panel A). TNFR2 mRNA levels of PBMC’s isolated from 10HCV(−) controls,
5 ALD/NAFLD controls, and 18 HCV+ patients prior to therapy were ascertained by real time PCR (Panel B). Statistical diﬀerences were
assessed by T-t e s t .
[SVR: Median 7.37 (Range: 0.29–35.92) versus NR/Rel:
Median 1.17 (Range: 0.08–15.91)] (Figure 2(a)).
The peak TNFR2 mRNA levels expressed in PBMC from
genotype 1HCV+ patients at 4, 8, 12, 24 or 48 weeks
were greater than 2 SD (8.6 fold elevation) above mean
control TNFR2 mRNA levels from HCV(−) patients in 3/12
(25%) SVR versus 3/20 (15%) genotype 1 NR and 0/4 (0%)
genotype 1 Rel. The peak TNFR2 mRNA levels from SVR
were not signiﬁcantly higher than the peak TNFR2 mRNA
levels from NR and Rel (P = .085) (Figure 2(b)). Similar
resultsofpeakTNFRlevelsinrespondersandnonresponders
were noted [median/range 6.1 (0.71–32.01) versus 2.98
(0.01–18.57) in Figure 2(b)]. Therefore, unlike peak PBMC
TNFR1 mRNA levels, peak PBMC TNFR2 mRNA levels
during IFN for all therapy were not signiﬁcantly diﬀerent
between SVR and nonresponders.
3.4. TNFR1 Expression by HCV+ SVR Patient’s PBMCs
Was Demonstrated by Western Blot Analysis. In order to
assess whether TNFR1 mRNA levels directly correlated with
diﬀerential expression of TNFR1 protein in a SVR or control
PBMCs, whole PBMC from a HCV+ SVR and a control
HCV(−) patient were lysed, assayed for protein content, and
20μg of protein per sample was loaded on a SDS PAGE
gel. Detection of the protein of −55kDa molecular weight
by anti-TNFR1 was observed in the PBMC of an HCV+
responder patient but was not observed in the HCV(−)
control PBMC lysate (Figure 3).
3.5. Increased TNFR1 Membrane Expression by Speciﬁc
Peripheral Blood Monocyte Subsets from SVR but Not NR Was
Observed. The surface expression of TNFR1 by PBMC in
HCV+ patients undergoing IFN/R has not been reported.
However, soluble TNFR1 has been described to be elevated
in patients with chronic HCV [6]. Because of the diﬀerences
noted in the TNFR1 mRNA levels between NR and the SVR,
ﬂow cytometric analysis of TNFR1 expression by PBMC
from a SVR and a NR was assessed. Whole PBMCs from
NR and SVR were isolated and stained with an FITC-
conjugated anti-TNFR1 Ab as described in the methods.
The PBMC of the HCV+SVR patient displayed 52% TNFR1
positive PBMC with mean ﬂuorescence intensity (MFI) of
80. The non-responding patient displayed 0.0% TNFR1
positivePBMC’s,withMFIof0.Asdemonstratedbytheﬂow6 Hepatitis Research and Treatment
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Figure 2: Peak TNFR1 mRNA values were higher in responder patients than nonresponder patients. TNFR1 mRNA levels of genotype
1HCV+ patients PBMC’s were ascertained by real time PCR. Twelve responders, 25NR/Rel and 12 responders, 24NR/Rel were assessed for
TNFR1 and TNFR2 mRNA levels, respectively (Panel A and B). Line indicates 2SD above mean control levels. Levels did not vary between
sample triplicates. Statistical diﬀerences were assessed by T test.
cytometric ﬁgure, the increase of TNFR1 levels was noted
in cells with light scatter characteristics of peripheral blood
monocytes or dendritic cells (Figure 4).
In order to further delineate which PBMC subset had
elevated levels of TNFR1 expression, TNFR1 MFI ratios
(TNFR1 MFI/isotype control MFI) were compared between
SVR, NR/Rel, and controls. HCV+ patients prior to therapy
and uninfected controls were noted to have similar TNFR1
MFI ratios in both the CD33+ (1.2 ± 0.01 (n = 2) versus
1.56 ± 0.37 (n = 2), resp. P = .19) and CD123+ PBMC
(1.14±0.56(n = 2)versus1.40±0.09,(n = 2)resp.,P = .57).
No diﬀerence was observed between the TNFR1 MFI ratios
from both CD33+ and CD123+ PBMC of the uninfected
controls and the NR (P = .4a n dP = 1.0, resp.).
In order to further assess the speciﬁc cell subset aﬀected
by IFNα,24PBMCsampleswerestainedwithCD123,CD33,
and TNFR-1 (16 SVR and 8 NR/Rel). Sixteen samples were
obtained from 5 SVR from weeks 62–48, and 8 samples
were taken from NR/Rel from weeks 5–81. A trend toward
a lower TNFR1 expression in CD123+ dendritic cells subset
was noted in the NR/Rel group (1.25 ± 0.45 versus 1.59 ±
0.42, P = .052). Of interest, a signiﬁcant diﬀerence was
n o t e db e t w e e nt h ep e a kv a l u eo fT N F RM F Ir a t i o( h i g h e s t
TNFR1 MFI ratio observed during therapy) in CD123+
PBMC isolated from SVR and NR/Rel (Table 3).
Further cell subset identiﬁcation was performed utilizing
an analysis by ﬂow sort using three cell markers to identify
the two cell subsets of dendritic cells: myeloid (MDC) and
plasmacytoid dendritic cells (PDCs). In the ﬁrst panel, the
control patient without chronic liver disease had virtually no
TNFR1 expression, in all 3 subsets, CD14 + CD123+, MDC
(CD11+ and CD123dim), and PDC (CD11− and CD123high)
(Figure 5(a)). However, in the second panel, after 48 weeks
of Ifn/R therapy, expression of TNFR1 in MDC and PDC in
the SVR was higher compared to the control (Figure 5(b))
In the non responder group the expression of TNFR1 was
similar to controls, low in all three subsets (Figure 5(c)).
Hence, upregulation of TNFR1 membrane expression in the
dendritic cell subset isolated from the SVR was noted.
3.6. TNFR1 mRNA Levels Increased during IFNα Based
Therapy and Was Isolated to the Plasmacytoid Dendritic Cells.
In order to determine when TNFR1 mRNA levels increased
during IFN for all based therapy, 13genotype 1SVR and
12 genotype 1NR or Rel were evaluated. In twenty-ﬁve
genotype 1 HCV+ patients enrolled in IFN/R therapy withHepatitis Research and Treatment 7
R
e
s
p
o
n
d
e
r
P
B
M
C
C
o
n
t
r
o
l
P
B
M
C
T
N
F
R
1
p
o
s
i
t
i
v
e
45
55
(kD)
Figure 3: TNFR1 protein expression was observed in PBMC’s from
HCV+responderpatient.WholePBMC’sfromarespondingHCV+
patient and a control HCV(−) patient were lysed and assayed for
protein content. Protein (20μg) was loaded for responder (lane
1) and HCV(−) patient (lane 2) and 0.2μg TNFR1 chimeric
protein positive control (lane 3) was loaded and subjected to SDS-
PAGE.
PBMC mRNA samples collected during the 48 weeks of
therapy, patients with SVR (n = 10) were more likely to have
increases in TNFR1 mRNA levels above mean control levels
thanpatientswithNR/Rel(n = 3)versus3/12(25%)NR/Rel.
Importantly, the peak levels in the NR/Rel were lower than
in the SVR (Tables 4(a) and 4(b)). Of interest, 4/7 (56%)
patients with elevated TNFR1 mRNA values during therapy
remained above mean control levels weeks after interferon
therapy discontinuation.
RNA from FAC sorted plasmacytoid dendritic cells
(PDCs) (CD11− and CD123high) and myeloid dendritic cells
(MDCs) (CD11+ and CD123dim) from a control, SVR, and
NR at 28 weeks of therapy were utilized in a real time PCR
assay for TNFR1. TNFR1 mRNA levels in PDC isolated from
a responder were 6.7 fold higher than the level of the control
PDC. No diﬀerence in TNFR1 mRNA levels was noted in
the control compared to responders MDC, non responders
MDC, or non responders PDC. TNFR 1 RNA level is higher
in the PDC isolated from patients with SVR than patients
with NR at 28 weeks (Figure 6).
4. Discussion
This study is the ﬁrst paper detailing the levels of TNFR
family member expression in PBMC samples from respon-
ders and nonresponders to IFN therapy for chronic HCV
over a 12-month period. Both TNFR1 and TNFR2 mRNA
levels in PBMC isolated during therapy were higher in
responders than control HCV(−) patients. Notably, the peak
values of PBMC TNFR1 mRNA during therapy were higher
in sustained virological responders than nonresponders or
relapsers. Furthermore, PBMC expression of other members
of the TNFR family remained stable during the course of
the therapy. Importantly, the TNFR1 mRNA upregulation
Table 3
Peak Values SVR NR/Rel P value
TNFR1 MFI Ratio N = 5 N = 6
CD33+ 2.2 ±0.56 1.54 ±0.57 .06
CD123+ 2.06 ±0.59 1.21 ±0.43 .01
Table 4: (a) TNFR1 mRNA Levels in genotype 1 SVR dur-
ing IFN based therapy. (b) TNFR1 levels in genotype 1 non-
responders/relapsers during IFN-based therapy.
(a)
week 0 week 4–12 14–24 wks 25–48 wks
Patient 1 0.96 7.83
Patient 2 1.39 7.13 1.97 0.71
Patient 3 4.23 7.61 3.86
Patient 4 8.44 23.48
Patient 5 0.15 0.63
Patient 6 6.42 19.77 11.73
Patient 7 0.87 0.82
Patient 8 0.29 1.45
Patient 9 0.15 11.46
Patient 10 1.24 1.52
Patient 11 0.43 35.93 8.04
Patient 12 0.06 18.20
Patient 13 0.29 0.22
(b)
week 0 week 4–12 14–24 25–48
Patient 1 1.53 4.73
Patient 2 0.67 1.14
Patient 3 2.73 0.17
Patient 4 2.61 0.98
Patient 5 2.97 6.54
Patient 6 0.64 4.07 0.16
Patient 7 1.25 2.71
Patient 8 2.83 1.20 0.34
Patient 9 0.26 0.10 0.11
Patient 10 0.73 0.15
Patient 11 0.08 0.05
Patient 12 0.46 0.14
occurred in a subset of PBMC, with cell surface markers
consistent with the dendritic cells.
Though other investigators have noted an increase in
soluble TNFR1 (sTNFR1) and soluble TNFR2 (sTNFR2)
in the serum of chronic HCV patients (18–21), this study
is the ﬁrst to note that the level of PBMC TNFR mRNA
rises over the course of IFN based therapy in responders.
Furthermore, others have noted that sTNFR2 appears to be
signiﬁcantly correlated with the severity of the disease and8 Hepatitis Research and Treatment
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Figure 4: Flow cytometry revealed an increased frequency of PBMC’s that expressed TNFR1 among responders. Whole PBMCs were stained
with FITC TNFR1 as described in the methods. Dot plots are noted on (a) and (b) with regions analyzed on each dot plot. (c) and (d)
demonstrate the responder and the nonresponder histograms of TNFR1 in the speciﬁc region outlined in (a) and (b).
ﬁbrosis[5].Asnotedinourpreviouspublications,50%–60%
of patients treated at the Dallas VA have stage 3 ﬁbrosis [18],
and in part enhanced TNFR1 expression at baseline may
be associated with ﬁbrosis scores. However, there have been
no signiﬁcant diﬀerences in ﬁbrosis between responders and
nonresponders to therapy in our patient population [18].
Though the upregulation of TNFR1 may be associated
with prolonged exposure to IFN, patients with multiple
sclerosis (MS) treated with long term type 1 IFN (interferon
beta) had stable PBMC TNFR 1 mRNA levels (data not
shown). Other mechanisms besides prolonged exposure to
t y p e1I F N ,i n v o l v e di nT N F R 1u p r e g u l a t i o nm a yi n c l u d e
clearance of HCV virus from speciﬁc cell types, allowing
further signaling from TNFR1 to NF6B, inducing TNFR1
upregulation [4]. Other mechanisms may relate to improved
antigenpresentation byAPC’s inspeciﬁc patient populations
after IFN exposure. Finally, speciﬁc patient populations may
have diﬀerent genetic polymorphisms of TNFR1, which
allow for enhanced viral clearance and upregulation of the
receptor’s mRNA, accounting for diﬀerences in response to
IFN based therapy.
Though there are limitations in the study in that less
than half of the patients with SVR had both initial and
long term followup, there is a suggestion that TNFR1 RNA
levels may increase in patients that respond and that this
i n c r e a s ea p p e a r sb er e l a t e dt oa nu p r e g u l a t i o no fT N F R 1o n
a dendritic cell subset. Though this represents only a portion
of the patients, the authors are suggesting that the ﬁndings in
this study bear reporting.
The ﬁnding that dendritic cell subset appears to be the
site of TNFR1 upregulation may provide insight into the
cause, these cells have been implicated as the cell among
PBMC that contains HCV negative RNA strand. Though
only a portion of the patients had extensive ﬂow cytometric
analysis, the results suggest that the dendritic cell is at least
one of the cells, where upregulation of TNFR1 occurs. WhileHepatitis Research and Treatment 9
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Figure 5: TNFR1 membrane expression is higher in dendritic cell subset in SVR compared to NR. Whole PBMCs from control HCV−,S V R
and NR were stained with PE-labeled CD123, FITC-labeled CD11, Texas Red-labeled CD14, and/or relative isotype controls as previously
described in the methods. CD11+, CD123dim ,C D 1 1 −, CD123high, and CD14+, CD11+ cell subsets were identiﬁed by 2-color analysis.
Signiﬁcant diﬀerences were noted in the expression of TNFR1 in the histogram from selected cell subset from a control HCV− (column a),
SVR (column b), and NR (column c).
recent reports suggest that PBMC’s from up to 67% of SVR
patientsstillexpressresidualHCVRNA,theselevelsarelikely
greatly reduced from pretherapy levels and relief of HCV-
mediated expression of TNFR family signaling may explain
reboundenhancedexpressionofTNFR1.Furthermore,these
APC’s have also been implicated as being critical for viral
clearance. Our study supports that within these cells, a
cell surface receptor, TNFR1, is disparately upregulated in
patients responding to IFN based therapy.
Initially, TNFR1 expression was noted to be upregulated
inCD123+dendriticcellsinpatientswithsustainedvirologi-
cal response. The data supports that at least in some patients
the increase in TNFR1 mRNA is predominantly found in the
plasmacytoid dendritic cells, an avid antigen presenting cell.
Importantly, upregulation of TNFR1 surface expression was
noted in one SVR patient’s myeloid dendritic cell, suggesting
that both types of dendritic cells may be important in HCV
viral clearance.10 Hepatitis Research and Treatment
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Figure 6: The increase in TNFR1 mRNA levels was isolated to the
plasmacytoid dendritic cells. RNA from FAC sorted plamacytoid
dendritic cells (PDC) (CD11− and CD123high) and myeloid den-
dritic cells (MDC) (CD11+ and CD123dim) from a control, SVR,
and NR were used in a real time PCR assay for TNFR1. Statistical
diﬀerences were assessed by T test.
In summary, TNFR1 mRNA and protein levels are
upregulated in dendritic cells. While the mechanism of this
upregulation has yet to be elucidated, this cell subset may
be involved in antigen presentation of viral proteins, and
TNFR1 levels may correlate with recovery of eﬀective APC
function.
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